

Robert G Micheletti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8386505/publications.pdf>

Version: 2024-02-01

118
papers

3,003
citations

185998

28
h-index

189595

50
g-index

122
all docs

122
docs citations

122
times ranked

2994
citing authors

#	ARTICLE	IF	CITATIONS
1	Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1092-1101.	0.6	77
2	Targeted Therapeutics: Biologics, Small Molecules. , 2022, , 182-190.		0
3	Clinical Characteristics, Disease Course, and Outcomes of Patients With Acute Generalized Exanthematous Pustulosis in the US. <i>JAMA Dermatology</i> , 2022, 158, 176.	2.0	31
4	Telemedicine and dermatology hospital consultations during the COVID-19 pandemic: a multicentre observational study on resource utilization and conversion to in-person consultations during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	0
5	Neutrophilic Dermatoses: a Clinical Update. <i>Current Dermatology Reports</i> , 2022, 11, 89-102.	1.1	14
6	Long-term sequelae from Stevens-Johnson syndrome/toxic epidermal necrolysis in a large retrospective cohort. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 784-786.	0.6	5
7	Use of teledermatology by dermatology hospitalists is effective in the diagnosis and management of inpatient disease. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1547-1553.	0.6	27
8	Low utility of radiologic imaging in evaluating cutaneous small-vessel vasculitis: A multi-institutional retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1197-1199.	0.6	3
9	Pregnancy in Hidradenitis Suppurativa—Patient Perspectives and Practice Gaps. <i>JAMA Dermatology</i> , 2021, 157, 227.	2.0	6
10	Reply. <i>Arthritis and Rheumatology</i> , 2021, 73, 1089-1089.	2.9	0
11	Advances in cutaneous vasculitis research and clinical care. <i>Annals of Translational Medicine</i> , 2021, 9, 439-439.	0.7	1
12	Cutaneous Manifestations of COVID-19: Characteristics, Pathogenesis, and the Role of Dermatology in the Pandemic. , 2021, 107, 209-215.		3
13	Authors' reply to the comment "High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa". <i>Journal of the American Academy of Dermatology</i> , 2021, 84, e203-e204.	0.6	0
14	Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus. <i>British Journal of Dermatology</i> , 2021, 185, 616-626.	1.4	22
15	Dermatologic support for oncology: Quantifying the consultative services received by hospitalized oncology patients. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 1367-1368.	0.6	1
16	Long-term Physical and Psychological Outcomes of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. <i>JAMA Dermatology</i> , 2021, 157, 712.	2.0	19
17	Corticosteroid use in chronic dermatologic disorders and osteoporosis. <i>International Journal of Women's Dermatology</i> , 2021, 7, 545-551.	1.1	2
18	Medical management of Stevens-Johnson syndrome/toxic epidermal necrolysis among North American dermatologists. <i>Journal of the American Academy of Dermatology</i> , 2021, , .	0.6	4

#	ARTICLE	IF	CITATIONS
19	Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor- α Inhibitors?. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 139-147.	3.3	6
20	Developing classification criteria for skin-predominant dermatomyositis: the Delphi process. <i>British Journal of Dermatology</i> , 2020, 182, 410-417.	1.4	25
21	Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: A retrospective chart review. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 507-510.	0.6	15
22	Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 366-376.	0.6	165
23	A survey-based study of diagnostic and treatment concordance in standardized cases of cellulitis and pseudocellulitis via teledermatology. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1221-1223.	0.6	18
24	Ablative fractional laser resurfacing for treatment of sclerosis and contractures in chronic graft-versus-host disease: A pilot study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 984-986.	0.6	4
25	High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1094-1101.	0.6	51
26	Creation of a Registry to Address Knowledge Gaps in Hidradenitis Suppurativa and Pregnancy. <i>JAMA Dermatology</i> , 2020, 156, 353.	2.0	14
27	Hidradenitis suppurativa encounters in a national electronic health record database notable for low dermatology utilization, infrequent biologic prescriptions, and frequent opiate prescriptions. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1239-1241.	0.6	3
28	Improving Outcomes for Patients With Epidermal Necrolysis. <i>JAMA Dermatology</i> , 2020, 156, 1289.	2.0	0
29	Management of cutaneous vasculitis. <i>Presse Medicale</i> , 2020, 49, 104033.	0.8	20
30	Calcinosis Cutis in the Setting of Chronic Skin Graft-Versus-Host Disease. <i>JAMA Dermatology</i> , 2020, 156, 814.	2.0	5
31	Protocol for a randomized multicenter study for isolated skin vasculitis (ARAMIS) comparing the efficacy of three drugs: azathioprine, colchicine, and dapsone. <i>Trials</i> , 2020, 21, 362.	0.7	14
32	Cutaneous Manifestations of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1741-1747.	2.9	31
33	Society of Dermatology Hospitalists supportive care guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1553-1567.	0.6	35
34	SJS/TEN 2019: From science to translation. <i>Journal of Dermatological Science</i> , 2020, 98, 2-12.	1.0	41
35	Diagnosis and management of Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>Clinics in Dermatology</i> , 2020, 38, 607-612.	0.8	22
36	Navigating immunosuppression in a pandemic: A guide for the dermatologist from the COVID Task Force of the Medical Dermatology Society and Society of Dermatology Hospitalists. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1150-1159.	0.6	27

#	ARTICLE	IF	CITATIONS
37	Retrospective review of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis cases at a pediatric tertiary care institution. <i>Pediatric Dermatology</i> , 2020, 37, 461-466.	0.5	18
38	A Multicenter Cross-Sectional Study and Systematic Review of Necrobiotic Xanthogranuloma With Proposed Diagnostic Criteria. <i>JAMA Dermatology</i> , 2020, 156, 270.	2.0	49
39	How Dermatologists Can Learn and Contribute at the Leading Edge of the COVID-19 Global Pandemic. <i>JAMA Dermatology</i> , 2020, 156, 733.	2.0	22
40	Cutaneous Manifestations of Sexually Transmitted Infections. , 2020, , 133-151.		0
41	Nutritional dermatoses in the hospitalized patient. <i>Cutis</i> , 2020, 105, 296;302-308;E1;E2;E3;E4;E5.	0.4	0
42	The ABCD-10 Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysisâ€”Reply. <i>JAMA Dermatology</i> , 2019, 155, 1088.	2.0	8
43	Skin and Soft Tissue Infection in Transplant Recipients. , 2019, , 365-395.		0
44	Continued weekly adalimumab is an effective strategy in patients with hidradenitis suppurativa who show at least partial response to therapy at week 12. <i>British Journal of Dermatology</i> , 2019, 181, 886-887.	1.4	0
45	Numerous Pink-Purple Papules in a Middle-aged Man. <i>JAMA Dermatology</i> , 2019, 155, 1308.	2.0	0
46	North American clinical management guidelines for hidradenitis suppurativa: AÂ”publication from the United States and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 91-101.	0.6	206
47	Bullous dermatosis suspected in an 8-month-old child in Guinea-Bissau. <i>Oxford Medical Case Reports</i> , 2019, 2019, omz004.	0.2	3
48	North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 76-90.	0.6	218
49	The potential costâ”savings of tumour necrosis factor inhibitors for hidradenitis suppurativa. <i>British Journal of Dermatology</i> , 2019, 180, 988-989.	1.4	2
50	Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysisâ€”ABCD-10. <i>JAMA Dermatology</i> , 2019, 155, 448.	2.0	69
51	Adverse drug reaction causality assessment tools for drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: room for improvement. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1135-1141.	0.8	16
52	Timing of mucocutaneous symptoms and medication discontinuation in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 1410-1412.	0.6	0
53	Reply to: â”œNew validated diagnostic criteria for pyoderma gangrenosumâ”œ. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, e89.	0.6	0
54	Erythematous plaques and nodules on the abdomen and groin. <i>Cutis</i> , 2019, 104, E24-E26.	0.4	0

#	ARTICLE	IF	CITATIONS
55	Neutrophilic dermatoses. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 1009-1022.	0.6	73
56	Neutrophilic dermatoses. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 987-1006.	0.6	122
57	Tobacco smoking and hidradenitis suppurativa: associated disease and an important modifiable risk factor. <i>British Journal of Dermatology</i> , 2018, 178, 587-588.	1.4	13
58	Cutaneous vasculitis in rheumatologic disease: Current concepts of skin and systemic manifestations. <i>Clinics in Dermatology</i> , 2018, 36, 561-566.	0.8	20
59	The Association of Age With Clinical Presentation and Comorbidities of Pyoderma Gangrenosum. <i>JAMA Dermatology</i> , 2018, 154, 409.	2.0	105
60	SJS/TEN 2017: Building Multidisciplinary Networks to Drive Science and Translation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 38-69.	2.0	134
61	Selective Use of Cyclosporine for Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis May Exclude Patients with Poor Prognostic Factors. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2068-2072.	0.3	7
62	Sweet syndrome in patients with and without malignancy: A retrospective analysis of 83 patients from a tertiary academic referral center. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 303-309.e4.	0.6	76
63	The immune reconstitution of the skin following sex-mismatched allogeneic haematopoietic stem cell transplant: a prospective case series utilizing fluorescence <i>in situ</i> hybridization and immunohistochemistry. <i>British Journal of Dermatology</i> , 2018, 178, e55-e56.	1.4	1
64	Introducing "Images in Dermatology". <i>JAMA Dermatology</i> , 2018, 154, 1255.	2.0	3
65	Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2315-2321.	0.3	94
66	Enlarging red papulonodule on the chest. <i>Cutis</i> , 2018, 101, 78;117;118.	0.4	0
67	Update on calciphylaxis etiopathogenesis, diagnosis, and management. <i>Cutis</i> , 2018, 102, 395-400.	0.4	2
68	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 191-198.	0.6	52
69	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 201-207.	0.6	115
70	216 A new mortality prediction tool for Stevens-Johnson syndrome/toxic epidermal necrolysis. <i>Journal of Investigative Dermatology</i> , 2017, 137, S37.	0.3	1
71	Pemetrexed-Induced Pseudocellulitis Reaction With Eosinophilic Infiltrate on Skin Biopsy. <i>American Journal of Dermatopathology</i> , 2017, 39, e1-e2.	0.3	12
72	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Standard Reporting and Evaluation Guidelines. <i>JAMA Dermatology</i> , 2017, 153, 587.	2.0	30

#	ARTICLE	IF	CITATIONS
73	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. Journal of the American Academy of Dermatology, 2017, 76, 1-9.	0.6	126
74	Prevention and management of glucocorticoid-induced side effects: A comprehensive review. Journal of the American Academy of Dermatology, 2017, 76, 11-16.	0.6	68
75	A cross-sectional survey of voriconazole prescribers: Assessing current practice and knowledge of cutaneous side effects. Journal of the American Academy of Dermatology, 2017, 77, 769-770.	0.6	2
76	Joseph Goldbergerâ€™Public Health Champion and Investigator of Pellagra. JAMA Dermatology, 2017, 153, 1262.	2.0	2
77	Robert Chesebrough and the Dermatologic Wonder of Petroleum Jelly. JAMA Dermatology, 2017, 153, 1157.	2.0	3
78	Bedside diagnostics in dermatology. Journal of the American Academy of Dermatology, 2017, 77, 197-218.	0.6	19
79	Bedside diagnostics in dermatology. Journal of the American Academy of Dermatology, 2017, 77, 221-230.	0.6	17
80	Atypical retiform hemangioendothelioma arising in a patient with Milroy disease: a case report and review of the literature. Journal of Cutaneous Pathology, 2017, 44, 98-103.	0.7	2
81	<i>Stenotrophomonas maltophilia</i> : an emerging multidrug-resistant opportunistic pathogen in the immunocompromised host. BMJ Case Reports, 2017, 2017, bcr-2017-221053.	0.2	9
82	Alopecia neoplastica. BMJ Case Reports, 2017, 2017, bcr-2017-220215.	0.2	5
83	Atypical Manifestations of Graft-Versus-Host Disease. , 2017, , 149-160.		1
84	Developing academic work and evidence to guide the practice of inpatient dermatology. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 35-37.	1.6	1
85	Medical management of hidradenitis suppurativa. Seminars in Cutaneous Medicine and Surgery, 2017, 36, 62-66.	1.6	3
86	Inter-rater reliability of cutaneous sarcoidosis assessment tools via remote photographic assessment. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2017, 34, 165-169.	0.2	1
87	Refractory Cutaneous Alternariosis Successfully Treated With Mohs Surgery and Full-Thickness Skin Grafting. Dermatologic Surgery, 2016, 42, 426-429.	0.4	2
88	Cryptococcal cellulitis in a heart transplant recipient. JAAD Case Reports, 2016, 2, 403-405.	0.4	1
89	Diffuse HIV-associated seborrheic dermatitis â€™ a case series. International Journal of STD and AIDS, 2016, 27, 1342-1345.	0.5	31
90	FLT3Inhibitorâ€™Associated Neutrophilic Dermatoses. JAMA Dermatology, 2016, 152, 480.	2.0	25

#	ARTICLE	IF	CITATIONS
91	Optimizing "best available" medical options when practicing complex medical dermatology in resource-limited settings. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, e171-e172.	0.6	0
92	Chronic idiopathic Sweet syndrome: A report of 2 cases. <i>JAAD Case Reports</i> , 2016, 2, 227-229.	0.4	5
93	Inpatient dermatology consultation in patients with hematologic malignancies. <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 835-836.	0.6	17
94	A small n sequential multiple assignment randomized trial design for use in rare disease research. <i>Contemporary Clinical Trials</i> , 2016, 46, 48-51.	0.8	31
95	Primary Cutaneous <i>Cryptococcus</i> in a Patient With Multiple Sclerosis Treated With Fingolimod. <i>JAMA Neurology</i> , 2016, 73, 355.	4.5	38
96	Small Vessel Vasculitis of the Skin. , 2016, , 233-244.		2
97	Purple curvilinear papules on the back. <i>Cutis</i> , 2016, 98, E5-E7.	0.4	0
98	Disseminated coccidioidomycosis masquerading as a ruptured epidermal inclusion cyst in a healthy young adult from Philadelphia. <i>International Journal of Dermatology</i> , 2015, 54, e441-e442.	0.5	0
99	The importance of multidisciplinary healthcare for paraneoplastic pemphigus. <i>Special Care in Dentistry</i> , 2015, 35, 143-147.	0.4	2
100	Cryptococcal meningitis presenting with headache and a pustular eruption in a heart transplant patient. <i>Transplant Infectious Disease</i> , 2015, 17, 716-718.	0.7	5
101	A Crusted Rash in a Patient With AIDS. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 298.	3.8	6
102	Atypical manifestations of graft-versus-host disease. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 690-695.	0.6	30
103	Small Vessel Vasculitis of the Skin. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 21-32.	0.8	58
104	An update on the diagnosis and treatment of hidradenitis suppurativa. <i>Cutis</i> , 2015, 96, 7-12.	0.4	8
105	Striking Follicular Eruption to Pegylated Liposomal Doxorubicin. <i>American Journal of Dermatopathology</i> , 2014, 36, 590-591.	0.3	7
106	Robotic teledermatopathology from an African dermatology clinic. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, 952-954.	0.6	8
107	Hidradenitis Suppurativa: Current Views on Epidemiology, Pathogenesis, and Pathophysiology. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, S48-S50.	1.6	32
108	Natural History, Presentation, and Diagnosis of Hidradenitis Suppurativa. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, S51-S53.	1.6	28

#	ARTICLE	IF	CITATIONS
109	What You Should Know About Hidradenitis Suppurativa: Information for Patients. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, S60-S61.	1.6	0
110	Introduction. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2014, 33, S47-S47.	1.6	4
111	A Violaceous Plaque in an Immunosuppressed Patient. <i>JAMA - Journal of the American Medical Association</i> , 2012, 307, 2635.	3.8	5
112	Distal Matrix Glomus Tumor Presenting as Longitudinal Erythronychia: A Pearl for Surgical Management. <i>Dermatologic Surgery</i> , 2012, 38, 133-134.	0.4	2
113	An Enlarging Ulcer. <i>American Journal of Medicine</i> , 2011, 124, 915-917.	0.6	0
114	An approach to the hospitalized patient with urticaria and fever. <i>Dermatologic Therapy</i> , 2011, 24, 187-195.	0.8	2
115	Coronary atherosclerotic lesions in human immunodeficiency virus-infected patients: a histopathologic study. <i>Cardiovascular Pathology</i> , 2009, 18, 28-36.	0.7	35
116	Calcification of the internal elastic lamina of coronary arteries. <i>Modern Pathology</i> , 2008, 21, 1019-1028.	2.9	34
117	Atherosclerotic oxalosis in coronary arteries. <i>Cardiovascular Pathology</i> , 2008, 17, 117-123.	0.7	42
118	MÃ¶nckeberg Sclerosis Revisited: A Clarification of the Histologic Definition of MÃ¶nckeberg Sclerosis. <i>Archives of Pathology and Laboratory Medicine</i> , 2008, 132, 43-47.	1.2	90